MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Moderate Buy” from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $74.46.

Several equities research analysts have recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $92.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 9th. Wolfe Research assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 15th. They issued an “outperform” rating and a $77.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They issued a “neutral” rating and a $62.00 price target for the company.

Insider Transactions at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $62.43, for a total transaction of $624,300.00. Following the transaction, the insider now directly owns 130,071 shares in the company, valued at $8,120,332.53. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Da Silva Jorge Santos sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $57.44, for a total transaction of $1,148,800.00. Following the sale, the chief executive officer now owns 3,107,554 shares of the company’s stock, valued at $178,497,901.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kristian Reich sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $62.43, for a total transaction of $624,300.00. Following the sale, the insider now directly owns 130,071 shares in the company, valued at approximately $8,120,332.53. The disclosure for this sale can be found here. Insiders have sold a total of 166,981 shares of company stock worth $9,490,674 over the last ninety days. 15.27% of the stock is currently owned by company insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its holdings in shares of MoonLake Immunotherapeutics by 956.6% in the second quarter. Osaic Holdings Inc. now owns 803 shares of the company’s stock valued at $41,000 after purchasing an additional 727 shares in the last quarter. Quarry LP purchased a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at about $51,000. Tower Research Capital LLC TRC purchased a new stake in shares of MoonLake Immunotherapeutics in the second quarter valued at about $47,000. Barclays PLC purchased a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $189,000. Finally, Stratos Wealth Partners LTD. purchased a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at about $202,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Down 0.3 %

Shares of MLTX stock opened at $43.50 on Friday. The stock has a market capitalization of $2.78 billion, a PE ratio of -57.24 and a beta of 1.20. The firm has a 50 day moving average of $51.27 and a two-hundred day moving average of $52.50. MoonLake Immunotherapeutics has a 52 week low of $18.43 and a 52 week high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.11. Analysts expect that MoonLake Immunotherapeutics will post -1.11 EPS for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.